Response of metastatic breast cancer to trastuzumab?

Lancet. 2000 Jan 15;355(9199):160-1. doi: 10.1016/S0140-6736(99)00430-4.

Authors

D M Barnes¹, D W Miles

Affiliation

¹ ICRF Breast Pathology Laboratory and ICRF Breast Biology Group, Guy's Hospital, London, UK.

PMID: 10675110
DOI: 10.1016/S0140-6736(99)00430-4

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Erb-b2 Receptor Tyrosine Kinases / metabolism
Female
Humans
Trastuzumab
United States
United States Food and Drug Administration

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Erb-b2 Receptor Tyrosine Kinases
Trastuzumab